Itinai.com an advertising picture for medical analysis labora e23355f1 1375 4542 a767 fc92f774dc1f 3
Itinai.com an advertising picture for medical analysis labora e23355f1 1375 4542 a767 fc92f774dc1f 3

Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults

Effects of NBI-1065845 on Drug Interactions in Healthy Adults

Study Overview

This study looked at the impact of NBI-1065845, a potential treatment for major depressive disorder, on the metabolism of midazolam and ethinyl estradiol-levonorgestrel in healthy adults. The results provide important insights into potential drug interactions.

Key Findings

After multiple doses of NBI-1065845, it was found that NBI-1065845 does not induce the CYP3A enzyme. This suggests that NBI-1065845 can be safely used with drugs metabolized by CYP3A.

Value for Clinical Practice

These findings support the safe coadministration of NBI-1065845 with CYP3A substrates, providing practical guidance for clinicians when prescribing medications.

Integrating Clinical Trials into Medical Practice

Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research, making it easier for clinicians to access important medical knowledge.

Streamlining Healthcare Operations

Efficient operations are essential in today’s healthcare environment. Our mobile apps support scheduling, treatment monitoring, and telemedicine, enabling clinics to manage patient care and expand services digitally.

Enhancing Workflows with AI

By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce paper-based routines. Learn more about how our solutions can benefit your practice at aidevmd.com.

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research